Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28810804 | 0.83 | LMNA (0.34) | LMNAMAPK1HTTCNR2CNR1 | |
| SCHEMBL8940095 | 0.82 | OR51E2 (0.40) | OR51E2 | |
| SCHEMBL12496608 | 0.79 | LMNA (0.35) | LMNAMAPK1HTTCNR2CNR1 | |
| SCHEMBL28090089 | 0.79 | PDE4A (0.41) | LMNAMAPK1HTT | |
| SCHEMBL27461223 | 0.78 | PDE4A (0.40) | LMNAMAPK1HTT | |
| Ethylene Glycol SCHEMBL21409533 | 0.77 | LMNA (0.37) | LMNAMAPK1HTTCNR2CNR1 | |
| SCHEMBL1907658 | 0.76 | MAPK1 (0.38) | LMNAMAPK1HTTCNR2CNR1 | |
| SCHEMBL111657 | 0.76 | MAPK1 (0.38) | LMNAMAPK1HTTCNR2CNR1 | |
| SCHEMBL1907659 | 0.76 | MAPK1 (0.38) | LMNAMAPK1HTTCNR2CNR1 | |
| SCHEMBL20548597 | 0.76 | CNR1 (0.47) | CNR2CNR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107875132-B | Felodipine sustained-release preparation composition and preparation method thereof | 常州市第四制药厂有限公司 | 2020-10-20 | — | — | CN | claimed |
| CN-117683001-A | Epoxy plasticizer and preparation method and application thereof | 宁波工程学院 | 2024-03-12 | — | — | CN | disclosed |
| US-20230287482-A1 | SYSTEMS AND METHODS FOR GENERATION OF EMULSIONS WITH SUITABLE CLARITY WITH APPLICATIONS OF USE | ENUMERIX INC (US) | 2023-09-14 | — | — | US | disclosed |
| EP-4135898-A1 | SYSTEMS AND METHODS FOR GENERATION OF EMULSIONS WITH SUITABLE CLARITY WITH APPLICATIONS OF USE | Enumerix, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-115697363-A | Composition for activating cell-killing T Cell (CTL) | DIC株式会社 | 2023-02-03 | — | — | CN | disclosed |
| CN-109890391-B | Treatment of dementia | 维斯塔实验室有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11542546-B2 | Systems and methods for generation of emulsions with suitable clarity with applications of use | ENUMERIX, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| CN-115443128-A | Pharmaceutical formulations | 阿斯利康(瑞典)有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-115443135-A | Dosage regimen for treating cancer | 阿斯利康(瑞典)有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20220339620-A1 | METHOD FOR PREPARING MICRO-CHANNEL ARRAY PLATE, DEVICE FOR OBTAINING LIQUID DROPS USING THE MICRO-CHANNEL ARRAY PLATE, AND METHOD FOR GENERATING LIQUID DROPS | ENUMERIX, INC. | 2022-10-27 | — | — | US | disclosed |
| US-11162136-B1 | Systems and methods for generation of emulsions with suitable clarity with applications of use | COUNTABLE LABS, INC. | 2021-11-02 | — | — | US | disclosed |
| US-20210324448-A1 | SYSTEMS AND METHODS FOR GENERATION OF EMULSIONS WITH SUITABLE CLARITY WITH APPLICATIONS OF USE | COUNTABLE LABS, INC. | 2021-10-21 | — | — | US | disclosed |
| WO-2021211758-A1 | SYSTEMS AND METHODS FOR GENERATION OF EMULSIONS WITH SUITABLE CLARITY WITH APPLICATIONS OF USE | ENUMERIX, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20210324459-A1 | SYSTEMS AND METHODS FOR GENERATION OF EMULSIONS WITH SUITABLE CLARITY WITH APPLICATIONS OF USE | COUNTABLE LABS, INC. | 2021-10-21 | — | — | US | disclosed |
| CN-107875132-B | Felodipine sustained-release preparation composition and preparation method thereof | 常州市第四制药厂有限公司 | 2020-10-20 | — | — | CN | disclosed |
| CN-107875132-B | Felodipine sustained-release preparation composition and preparation method thereof | 常州市第四制药厂有限公司 | 2020-10-20 | — | — | CN | disclosed |
| CN-109890391-A | treatment of dementia | 维斯塔实验室有限公司 | 2019-06-14 | — | — | CN | disclosed |
| US-20110021621-A1 | Drug for treating circulatory insufficiency | ACTIVUS PHARMA CO., LTD. (JP) | 2011-01-27 | — | — | US | disclosed |
| US-20090099256-A1 | Drug for Treating Circulatory Insufficiency | ACTIVUS PHARMA CO., LTD. (JP) | 2009-04-16 | — | — | US | disclosed |
| EP-1950209-A1 | AGENT FOR TREATMENT OF CIRCULATORY FAILURE | ACTIVUS PHARMA CO., LTD. (JP) | 2008-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021621-A1 | Drug for treating circulatory insufficiency | NPR1, TNNI3, NPR3 | LMNA 2637/4885MAPK1 928/4885HTT 4469/4885 |
| US-20090099256-A1 | Drug for Treating Circulatory Insufficiency | NPR1, TNNI3, NPR3 | LMNA 2637/4885MAPK1 928/4885HTT 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.